Metastatic refractory Pancreatic Cancer research hub

PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.

The PaTcH trial is testing whether combining two medications, trametinib and hydroxychloroquine, can help control advanced pancreatic cancer. It is designed for adults whose cancer has spread and no longer responds to standard treatments. Researchers want to see if these tablets can keep tumours stable for at least 12 weeks.